Table 1.
Cut offs for biochemical tests below which the respondents would enrol patients into the proposed trial
| THRESHOLD |
OVERALL (%) |
UK (%) |
ANZ (%) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| ALT/AST | CK | BILIRUBIN | ALT/AST | CK | BILIRUBIN | ALT/AST | CK | BILIRUBIN | |
|
uln |
27.6 |
34.7 |
33.9 |
31.6 |
41.8 |
38.4 |
16.1 |
14.5 |
21.0 |
|
3 uln |
42.3 |
33.9 |
37.7 |
36.7 |
26.0 |
32.2 |
58.1 |
56.5 |
53.2 |
|
5 uln |
13.8 |
13.4 |
12.1 |
11.3 |
10.7 |
8.5 |
21.0 |
21.0 |
22.6 |
|
10 uln |
2.5 |
2.9 |
1.7 |
2.3 |
2.8 |
1.7 |
3.2 |
3.2 |
1.6 |
|
>10 uln |
0.4 |
1.7 |
1.3 |
0 |
0.6 |
1.1 |
1.6 |
4.8 |
1.6 |
|
missing/no response |
13.4 |
13.4 |
13.4 |
18.1 |
18.1 |
18.1 |
0 |
0 |
0 |
| total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Shows the biochemical cut offs for hepatic transaminases (ALT/AST), creatine kinase (CK) and total bilirubin (bilirubin) below which the respondents would consider enrolling patients in the proposed statin interventional trial. Data are presented as proportions. ULN = upper limit of normal. p = 0.007 for ALT/AST; p < 0.001 for CK; p = 0.003 for Bilirubin (p-values when comparing the overall frequency distribution of the responses for ANZ and UK).